ECSP20057847A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents

Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Info

Publication number
ECSP20057847A
ECSP20057847A ECSENADI202057847A ECDI202057847A ECSP20057847A EC SP20057847 A ECSP20057847 A EC SP20057847A EC SENADI202057847 A ECSENADI202057847 A EC SENADI202057847A EC DI202057847 A ECDI202057847 A EC DI202057847A EC SP20057847 A ECSP20057847 A EC SP20057847A
Authority
EC
Ecuador
Prior art keywords
stimulator
cyclopentane
interferon genes
compounds
sting modulators
Prior art date
Application number
ECSENADI202057847A
Other languages
English (en)
Inventor
Martin James Wythes
Ketan S Gajiwala
Indrawan James Mcalpine
Andreas Maderna
Eugene Yuanjin Rui
Andrew Fensome
Mehran Jalaie
Ryan Patman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP20057847A publication Critical patent/ECSP20057847A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Consiste en compuestos de la fórmula general (I), conforme se puede evidenciar en el resumen contenido en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, procesos para la preparación de estos compuestos, composiciones que contiene estos compuestos, y los usos de estos compuestos.
ECSENADI202057847A 2018-03-15 2020-09-15 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano ECSP20057847A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25

Publications (1)

Publication Number Publication Date
ECSP20057847A true ECSP20057847A (es) 2021-04-29

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202057847A ECSP20057847A (es) 2018-03-15 2020-09-15 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Country Status (24)

Country Link
US (4) US10538542B2 (es)
EP (1) EP3765474B1 (es)
JP (1) JP7266942B2 (es)
KR (1) KR20200131878A (es)
CN (1) CN111918871A (es)
AU (1) AU2019234043A1 (es)
BR (1) BR112020018593A2 (es)
CA (1) CA3093631C (es)
CL (1) CL2020002352A1 (es)
CR (1) CR20200382A (es)
DO (1) DOP2020000160A (es)
EC (1) ECSP20057847A (es)
ES (1) ES2923298T3 (es)
IL (1) IL277278A (es)
MA (1) MA52012A (es)
MX (1) MX2020009587A (es)
NI (1) NI202000058A (es)
PE (1) PE20210412A1 (es)
PH (1) PH12020551486A1 (es)
RU (1) RU2020130048A (es)
SG (1) SG11202008102VA (es)
TW (1) TWI741268B (es)
UY (1) UY38145A (es)
WO (1) WO2019175776A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR20200140867A (ko) 2018-04-06 2020-12-16 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
MX2022003633A (es) * 2019-09-25 2022-04-19 Pfizer Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
JPWO2021206158A1 (es) 2020-04-10 2021-10-14
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ES2692226T3 (es) * 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
CN111918871A (zh) 2020-11-10
CA3093631A1 (en) 2019-09-19
BR112020018593A2 (pt) 2020-12-29
ES2923298T3 (es) 2022-09-26
CA3093631C (en) 2023-01-24
TW201945036A (zh) 2019-12-01
US20190284216A1 (en) 2019-09-19
EP3765474A1 (en) 2021-01-20
NI202000058A (es) 2021-01-08
US20200102334A1 (en) 2020-04-02
AU2019234043A1 (en) 2020-09-17
MA52012A (fr) 2021-01-20
MX2020009587A (es) 2020-10-05
IL277278A (en) 2020-10-29
US10968242B2 (en) 2021-04-06
UY38145A (es) 2019-10-31
US20210230196A1 (en) 2021-07-29
US20230382932A1 (en) 2023-11-30
RU2020130048A (ru) 2022-04-15
EP3765474B1 (en) 2022-06-15
JP2021518335A (ja) 2021-08-02
SG11202008102VA (en) 2020-09-29
DOP2020000160A (es) 2020-09-30
CR20200382A (es) 2020-12-10
CL2020002352A1 (es) 2020-12-18
TWI741268B (zh) 2021-10-01
RU2020130048A3 (es) 2022-04-15
PH12020551486A1 (en) 2021-08-23
JP7266942B2 (ja) 2023-05-01
KR20200131878A (ko) 2020-11-24
WO2019175776A1 (en) 2019-09-19
PE20210412A1 (es) 2021-03-04
US10538542B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CL2020000299A1 (es) Compuestos, composiciones y métodos.
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2018002060A2 (es) Compuestos farmacéuticos
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
DOP2016000316A (es) Dinucleótidos cíclicos como moduladores de sting
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
UY37098A (es) Moduladores de ror-gamma
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP20029790A (es) Compuestos moduladores de sting y métodos de elaboración y uso
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019001106A1 (es) Composición para aliviar o tratar el dolor.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano